Creative Planning
RCUS icon

Creative Planning’s Arcus Biosciences RCUS Stock Holding History

Creative Planning’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$722K Buy
33,445
+2,073
+7% +$44.8K ﹤0.01% 2735
2025
Q4 		$748K Buy
31,372
+1,743
+6% +$35.6K ﹤0.01% 2507
2025
Q3 		$403K Buy
29,629
+771
+3% +$8.02K ﹤0.01% 2917
2025
Q2 		$235K Buy
+28,858
New +$246K ﹤0.01% 3101
2025
Q1 		– Sell
-79
Closed -$1.18K – 3677
2024
Q4 		$1.18K Buy
+79
New +$1.29K ﹤0.01% 3514

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Creative Planning's RCUS Position: Q1 2026 in Review

Creative Planning increased its Arcus Biosciences (RCUS) stake by 6.6% in Q1 2026, buying an estimated $44.8K and bringing the position to 33,445 shares worth $722K. The position accounts for ﹤0.01% of the portfolio, ranked #2735.

Creative Planning first reported a position in RCUS in Q4 2024 and has held it in 5 quarters since. The position peaked at $748K in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Creative Planning held 33,445 shares of Arcus Biosciences worth $722K as of Q1 2026.
  • Creative Planning bought 2,073 Arcus Biosciences shares in Q1 2026, an estimated $44.8K.
  • Arcus Biosciences made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #2735 holding.
  • Creative Planning first reported a position in Arcus Biosciences in Q4 2024 and has held it in 5 quarters since.
  • Creative Planning's Arcus Biosciences position peaked at $748K in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.